## Fruzaqla (fruquintinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:			
important for the review (	• • •		ch any additional documentation that is zation request). Information contained in		
			URGENT		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH	DATE OF BIRTH:		
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID	NUMBER:	-			
IF YOU ARE NOT THE PATIENT OR THE PR FOLLOWING LINK: PRIMETHERAPEUTICS.	RESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISC COM/NOPP	CLOSURE AUTHORIZATION FO	ALLERGIES:		
AUTHORIZED REPRESENTA	ATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATI	ON				
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:					
CITY:		STATE:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTAC	OFFICE CONTACT PERSON:		
MEDICATION OR MEDIC	AL DISPENSING INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFIL	QUANTITY: LS:		
NEW THERAPY DURATION OF THERAPY (	RENEWAL (SPECIFIC DATES):	IF RENEWAL: DA	ATE THERAPY INITIATED:		

Prime

Continued on next page

## Fruzaqla (fruquintinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
<ul> <li>□ Metastatic colorectal cancer(mCRC)</li> <li>□ Other diagnosis:</li> </ul>	ICD-10 Code(s):		
PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A	
Is patient going to be using drug in a c	linical trial?   Yes   No		
Did patient progress on or was intoler Stivarga(regorafenib) or both? ☐ Yes	rant to treatment with either Lonsurf(tri	fluridine/tipiracil) or	
Has patient been previously treated v Yes □ No Please submit documentat	vith fluoropyrimidine-, oxaliplatin-, and ion.	irinotecan-based chemotherapy? □	
Has patient been previously treated v	with an anti-VEGF therapy?   Yes   No	Please submit documentation.	
Is patient's tumor RAS wild-type? $\Box$ Y	'es □ No Please submit documentation	ı <b>.</b>	
If patient's tumor is RAS wild-type, an Yes □ No Please submit documentat	id medically appropriate, was patient tracion.	eated with an anti-EGFR therapy? $\Box$	
Does patient have microsatellite-high submit documentation.	(MSI-H) or mismatch repair deficient (d	MMR) tumors? 🗆 Yes 🗆 No Please	
	-H) or mismatch repair deficient (dMMI	· ·	
Was patient ineligible for treatment v	vith a checkpoint inhibitor?   Yes   No	Please submit documentation.	
Does patient have an Eastern Coopera	ative Oncology Group (ECOG) performar	nce status of 0-1?	
Does patient have BRAF-mutant tumo	ors?   Yes   No Please submit docume	ntation.	
If patient has a BRAF-mutant tumor, v documentation.	was patient treated with a BRAF inhibito	or? □ Yes □ No Please submit	



## Fruzaqla (fruquintinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER 2 TA21 NAME:	MEMBER 2 FIR21 NAME:		
Was the patient ineligible for treatment with a BRAF inhibitor? ☐ Yes ☐ No Please submit documentation. Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?			
Please note: Not all drugs/diagnosis are covered information is received.	d on all plans. This request may be denied unless all required		
•	d is true and accurate to the best of my knowledge. I understand that esignees may perform a routine audit and request the medical the information reported on this form.		
Prescriber Signature or Electronic I.D. Verificati	ion: Date:		
you are not the intended recipient, you are hereby notified	this transmission contain confidential health information that is legally privileged. If d that any disclosure, copying, distribution, or action taken in reliance on the contents wed this information in error, please notify the sender immediately (via return FAX) ents.		

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811

Phone: 877-228-7909

